Companies are investing heavily in complex injectables, respiratory therapies and biosimilars to improve margins and diversify portfolios.
Pharma major Lupin is significantly increasing its focus on biosimilars, aiming for a turnover of nearly $500 million from this segment over the next five years, driven by new product launches and expanded presence in key global markets like the US, Europe, and Japan.
Torrent Pharma has emerged as a top sectoral pick for brokerages, driven by healthy growth in India revenues and improved gross margins, leading to a 44 per cent stock return over the past year.
Sun Pharmaceutical Industries reported a 27 per cent year-on-year increase in consolidated net profit to 2,894.7 crore for Q1FY27, with revenue growing 10 per cent to 15,299.8 crore, driven by strong performance in India and innovative medicines.
Indian benchmark indices, Sensex and Nifty, ended marginally lower after recovering from sharp intraday losses, driven by cooling crude oil prices and buying interest in HDFC Bank and IT sector stocks.
The Bombay High Court severely criticised the Maharashtra FDA for its "undue haste" and "high-handed" actions, forcing the regulator to withdraw orders against Cipla Pharma and five restaurants at the Mumbai Cricket Association premises. The court admonished the FDA for violating principles of natural justice and taking a "pedantic instead of pragmatic view," even threatening contempt action against officials.
Shares of Symbiotec Pharmalab Ltd, a pharma and biotech company, made a muted market debut, listing nearly 1 per cent lower on the BSE against its issue price of Rs 988, but later recovered to trade higher.
Sun Pharmaceutical Industries reported strong consolidated numbers for Q4 FY26, with net profit rising 26 per cent year-on-year to 2,714 crore, despite continued weakness in its US generics business. Growth in innovative medicines and increased R&D investments are helping to offset these pressures.
Indian benchmark indices, Sensex and Nifty, traded flat in early deals due to elevated crude oil prices exceeding USD 100 per barrel and persistent geopolitical tensions, which subdued investor risk appetite.
Indian benchmark indices, Sensex and Nifty, saw declines in early trade due to escalating crude oil prices and ongoing US-Iran hostilities, which subdued investor risk appetite.
Indian pharmaceutical companies are strategically increasing investments in the US market, focusing on specialty drugs, complex generics, respiratory products, and local manufacturing, despite a nearly 10 per cent fall in exports to the US in FY26 due to pricing pressure and competition in traditional generics.
India's white-collar job market experienced a 14 per cent year-on-year growth in August, with the auto, healthcare, and retail sectors leading the surge, according to a report by Naukri.com.
The World Health Organization has requested information from the Indian government regarding the alleged supply of spurious oxytocin injections linked to the deaths of five women in Kota hospitals. This comes after regulatory action, including the cancellation of manufacturing licenses for Jackson Laboratories units, following joint inspections by drug control bodies. The government is investigating the matter, emphasising a zero-tolerance approach to quality violations.
Piramal Pharma anticipates a significant turnaround in financial year 2026-27 (FY27), projecting early-to-mid teens revenue expansion and a sharp improvement in profitability, driven by improved business momentum, new product acquisitions, and structural tailwinds.
Five Raksha Bandhan ads that stayed with us long after the festival was over...
'India is vulnerable to the West Asia crisis in three ways: Energy costs, the business Indian companies conduct in the region, and remittances from the Indian diaspora.'
Indian stock markets closed lower due to selling in IT and FMCG shares, triggered by renewed tensions in West Asia which led to a rally in crude oil prices and concerns over inflation and interest rates.
US Ambassador to India, Sergio Gor, highlighted the evolving US-India space partnership, moving from cooperation to "co-creation" at the Bengaluru Space Expo. He emphasised joint design, funding, and co-authoring the future of human discovery, citing the NISAR satellite and India's participation in the Artemis Accords as key examples of this growing synergy.
Indian benchmark indices Sensex and Nifty experienced a significant slump in early trade, mirroring a bearish trend in global equities, as escalating conflict in West Asia drove up crude oil prices and intensified investor concerns.
Indian benchmark indices, Sensex and Nifty, continued their downward trend for the fifth consecutive day, with the Sensex dropping 281 points and Nifty falling 78 points, primarily driven by surging crude oil prices and persistent geopolitical tensions in West Asia.
Sun Pharmaceutical Industries Ltd has announced its acquisition of US-based Organon & Co in an all-cash deal valued at an enterprise valuation of USD 11.75 billion, aiming to become a top 25 global pharmaceutical company.
Sun Pharmaceutical Industries' Executive Chairman Dilip Shanghvi described the USD 11.75 billion acquisition of US-based Organon & Co as both a "happy" and "bit anxious" moment, acknowledging the significant debt required to fund the large transaction.
In the next 36 months nearly 25 to 40 per cent of jobs will be under threat from AI and job losses are inevitable.
Indian benchmark indices Sensex and Nifty rebounded in early trade after three days of decline, driven by a rally in Sun Pharma following its USD 11.75 billion acquisition of US-based Organon & Co, alongside a positive trend in global equity markets.
The Maharashtra Food and Drug Administration (FDA) has cancelled the licences of 10 Ayurvedic drug manufacturing units and issued show-cause notices to 135 others following inspections that revealed serious violations including unhygienic conditions, lack of technical staff, and inadequate testing protocols.
Indian benchmark equity indices, Sensex and Nifty, closed lower for multiple consecutive days, with the Nifty extending its losses to a seventh day, primarily due to elevated crude oil prices following the expiry of the US-Iran ceasefire without a diplomatic resolution.
Indian benchmark equity indices, Sensex and Nifty, experienced declines in early trade due to elevated crude oil prices and persistent geopolitical uncertainties, particularly following the expiry of the US-Iran ceasefire. Track Sensex, Nifty on August 19, 2026.
Indian benchmark indices Sensex and Nifty experienced declines in early trade, driven by a surge in Brent crude oil prices above USD 91 per barrel due to escalating tensions between Iran and the US, alongside an increase in US 10-year bond yields. Track Sensex, Nifty on August 18.
Odisha-based Serendipity Space successfully demonstrated drug crystallisation processes on a satellite prototype in a near-space mission. This breakthrough aims to enable pharmaceutical manufacturing in low Earth orbit, leveraging microgravity to create superior drug crystal structures for enhanced solubility, stability, and effectiveness. The mission tested core technologies, including an autonomous pharmaceutical factory, and was inspired by advancements made on the International Space Station.
'Improved law and order and transparent governance have helped change UP's investment image.'
India's 10 most valuable families had a combined valuation of Rs 70.5 trillion.
At the heart of this debate is Section 3(d) of the Patents Act, a safeguard designed to prevent drugmakers from extending monopoly protection through trivial modifications to existing medicines.
Sun Pharmaceutical Industries' acquisition of US-based Organon & Co. for $11.75 billion, the largest overseas acquisition by an Indian pharma company, has been met with mixed reactions from brokerages, who see strategic entry into women's health and biosimilars but also flag potential integration challenges and debt concerns.
Indian benchmark indices, Sensex and Nifty, experienced declines in early trade due to a surge in crude oil prices and significant selling pressure on bank stocks, impacting overall investor sentiment. Track Sensex, Nifty on July 22.
Combine a robust base health plan with a super top-up, critical illness cover and a dedicated medical corpus to protect household finances from soaring treatment costs.
US President Donald Trump announced steep tariffs on imported generic medicines, effective from August 2028, with the aim of boosting domestic pharmaceutical production. This policy, which includes a phased increase in tariffs up to 200 per cent, could significantly impact India, a major global supplier of generic drugs to the US market.
Indian stock market benchmark indices, Sensex and Nifty, saw significant gains in early trade, driven by a sharp decline in crude oil prices and easing geopolitical tensions, alongside renewed foreign fund inflows.
Indian benchmark stock indices, Sensex and Nifty, extended their winning streak to a fourth day, with Nifty surging 1.60 per cent, driven by a sharp decline in crude oil prices and renewed foreign fund inflows.
India's outward foreign direct investment (FDI) plummeted by 47.9 per cent year-on-year to $3 billion in June 2026, according to the Reserve Bank of India (RBI), with declines across equity, debt, and guarantee commitments.
Indian benchmark indices, Sensex and Nifty, opened in positive territory, primarily driven by a strong performance in IT stocks, sustained foreign fund inflows, and a dip in global crude oil prices, despite a hawkish stance from the US Federal Reserve. Track Sensex, Nifty on July 30.
